RATIONALE Mitochondrial nephropathy has a poor prognosis and often progresses to the end-stage renal disease. Renal pathology often is focal segmental glomerulosclerosis (FSGS) and does not respond to steroid therapy or immunosuppressive therapy. Some patients are benefited from the therapy of coenzyme Q10, which affect the synthesis pathway of coenzyme Q10. PATIENT CONCERNS Herein, we report...

Article history: Received 29 March 2013 Available online 10 February 2014 JEL classification: C72 D83 D85

Article history: Received 30 November 2007 Available online 31 August 2011 JEL classification: D82 D83

Article history: Received 3 September 2010 Available online 21 June 2011 JEL classification: C72 D82

Article history: Received 2 August 2007 Available online 14 January 2015 JEL classification: C78 D83

Article history: Received 13 April 2016 Available online 28 December 2016 JEL classification: D83

Article history: Received 13 July 2009 Available online xxxx JEL classification: C72 D82

Article history: Accepted 25 February 2013 JEL classification: G12 G14 E43

Article history: Received 8 May 2008 Available online 5 August 2009 JEL classification: A14 D20 J00